Clinical Trials List
Protocol NumberCAAA817B12301
Active
2025-08-01 - 2032-12-31
Phase III
Recruiting2
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 沈鼎文 無
- Kai-Jie Yu 無
- See-Tong Pang 無
- Yung-Chang Lin 無
- Kung-Chu Ho 無
- Po-Jung Su Division of Hematology & Oncology
- PO-HUNG LIN 無
- Hong-Cheng Gan 無
- Jing-Ren Tseng Division of Nuclear Medicine
- 黃意方 無
- I-hung Shao 無
- Rita cheng 無
- 黃文冠 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
18 participants
-
Global
605 participants
